2024
EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol
Petrillo A, Oudijk L, Sundar R, Daumer C, Casas J, D’Haese D, Mauer M, van Grieken N, Smyth E, Moehler M. EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol. ESMO Gastrointestinal Oncology 2024, 5: 100071. DOI: 10.1016/j.esmogo.2024.100071.Peer-Reviewed Original Research
2022
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
Yeong J, Lum H, Teo C, Tan B, Chan Y, Tay R, Choo J, Jeyasekharan A, Miow Q, Loo L, Yong W, Sundar R. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer 2022, 25: 741-750. PMID: 35661944, PMCID: PMC9226082, DOI: 10.1007/s10120-022-01301-0.Peer-Reviewed Original ResearchConceptsCombined positive scorePD-L1 combined positive scoreTumor proportion scorePD-L1Gastric cancerImmune cellsPD-L1 immunohistochemistry assaysProgrammed death-ligand 1Resection of gastric cancerStandard-of-care treatmentBackgroundImmune checkpoint inhibitorsGastric cancer immunotherapyPD-L1 positivityPD-L1 scoringPD-L1 immunohistochemistryDeath-ligand 1Metastatic gastric cancerPD-L1-positive samplesInter-assay concordanceCheckpoint inhibitorsDako 22C3ICI therapyCross-sectional studyCancer immunotherapyPatient selectionChoice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.
Tay R, Yeong J, Lum J, Teo C, Tan B, Chan Y, Choo J, Jeyasekhran A, Miow Q, Loo L, Yong W, Sundar R. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Journal Of Clinical Oncology 2022, 40: 4026-4026. DOI: 10.1200/jco.2022.40.16_suppl.4026.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune checkpoint inhibitor therapyPD-L1 CPSTumor proportion scorePD-L1Gastric cancerTissue microarrayImmune cellsPatients treated with ICI therapyPD-L1 expression statusPD-L1 immunohistochemistry assaysProgrammed death-ligand 1Resection of gastric cancerStandard-of-care treatmentGastric cancer immunotherapyPD-L1 scoringPD-L1 immunohistochemistryPD-L1 positivityDeath-ligand 1Metastatic gastric cancerPD-L1-positive samplesInter-assay concordanceNational University HospitalWhole slide analysisCut-off
2021
Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
Zhao J, Yap D, Chan Y, Tan B, Teo C, Syn N, Smyth E, Soon Y, Sundar R. Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2021, 40: 392-402. PMID: 34860570, DOI: 10.1200/jco.21.01862.Peer-Reviewed Original ResearchConceptsProgrammed death-ligand 1Combined positive scoreImmune checkpoint inhibitorsKEYNOTE-062First-line treatmentCheckMate-649Checkpoint inhibitorsEsophageal adenocarcinomaKaplan-MeierEstimate time-to-event outcomesFirst-line immune checkpoint inhibitorsPD-L1 combined positive scoreProgrammed death ligand 1 subgroupsPatients treated with pembrolizumabPD-L1-expressing tumorsRandomized phase III trialEfficacy of ICIsPD-L1 subgroupsProgression-free survivalDeath-ligand 1Phase III trialsUS Food and Drug AdministrationPrimary manuscriptsFood and Drug AdministrationCPS-1